AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph at page 4, lines 8-9, with the following rewritten paragraph:

-- **Fig. 2** shows schematically an experimental set-up, used to investigate the hypothesised trans-phosphorylation of Btk (Bruton's Tyrosine Kinase). In both the top and bottom depictions, the top left sequence is SEQ ID NO: 5, the bottom left sequence is SEQ ID NO: 6, the top right sequence is SEQ ID NO: 7, and the bottom right sequence is SEQ ID NO: 8. --

Please replace the paragraph at page 13, line 26, to page 14, line 7, with the following rewritten paragraph:

-- Peptide-nucleic-acid-linker$_3$-peptide (=ligand) fusions were generated as described before (Brandén LJ, Mohamed AJ, Smith CIE. A peptide nucleic acid-nuclear localisation signal fusion that mediates nuclear transport of DNA. *Nature Biotechnol* 17:784-787, 1999). The following functional entities were tested: The trimer amino-acid, arginine-glycine-aspartic acid (rgd, using the single letter code for amino acid residues, FE1, also designated RGD), the Human immunodeficiency virus (HIV) peptide TAT (grkkrrqrrrppqc (SEQ ID NO: 3), FE2) and the peptide "BULKY", which is a branched peptide with the following sequence 8*kafrsaaq (SEQ ID NO: 4) (FE3 and FE4), where 8* indicates branched lysines, the first residues following the lysine (k) being 2 lysines, followed by 4

lysines and 8 lysine residues in the end. The branched peptide was either untreated (designated charged, FE3) or acetylated (designated uncharged, FE4) to reduce the charge from the lysine residues. The TAT peptide-nucleic-acid-linker$_3$-peptide (=ligand) fusion hybridised specifically to the target site, Seq. Id. No. 2, whereas all the other constructs hybridised to the two peripheral target sites, Seq. Id. No. 1. --

In the Sequence Listing:

Please insert the attached Sequence Listing (in paper copy and computer readable form (CRF)) to the end of the specification, and re-number the pages accordingly.

In the Abstract:

Please cancel the Abstract of record, and add the accompanying new Abstract of the Disclosure which appears on a separate sheet in the Appendix.